WPSS.bio

Blackrock Neurotech’s mission is to provide innovative tools and neurotech expertise to translate technology into a novel, implantable clinical solutions that improve human lives.

Ceretype Neuromedicine is an AI-based fMRI brain biomarker technology to improve drug discovery and patient care. Based in Cambridge Massachusetts, Ceretype is founded on seminal scientific discoveries made in the laboratory of Emily Stern, David Silbersweig, and Hong Pan at Brigham and Women’s Hospital/Harvard Medical School (BWH/HMS).

Ksana Health focuses on collecting data related to mental health and transfer that data from users to healthcare practitioners through an app.

OccamzRazor is a San Francisco-based AI-neuroscience startup dedicated to developing disease-modifying treatments for Parkinson's Disease and other complex ailments. The company employs a computational approach that leverages both structured and unstructured biomedical data, including published literature and clinical trial results. By constructing a comprehensive knowledge graph that encapsulates all known information about Parkinson's Disease, OccamzRazor facilitates enhanced therapeutic insights and informed decision-making in biomedical research. This platform aims to identify new therapeutic targets and support strategic drug development, addressing the multifactorial nature of complex diseases like Parkinson's.

Sana Health UK Limited develops a sleep mask for people with severe sleep problems caused by high anxiety or pain. The company offers Sana, a wearable device that allows the wearer to put themselves to sleep in 10 minutes. Its mask measures and tracks user’s overall state of health and vitality over time, and uses this measure to tailor the device to get user to deep relaxation and sleep fast. Sana Health UK Limited was founded in 2015 and is based in Dorchester, United Kingdom.

Developer of clinical-stage neuroscience therapeutics intended to harness novel neuroplasticity-promoting treatments for difficult-to-treat neuropsychiatric and neurological disorders. The company's compounds include non-hallucinogenic, non-psychotomimetic, and non-dissociative versions of psychedelic components, enabling healthcare service providers to address significant mental health challenges through phenotypic drug discovery across various chemotypes and mechanisms of action.

Developer of a bio-computational platform designed to extract valuable insights from a variety of sample types. The company's platform provides end-to-end services including custom panel development, data acquisition utilizing its imaging technology and spatial data analysis, enabling guide researchers, drug developers and physicians to generate cellular maps that assist in drug discovery.

Perception Neuroscience is a biopharmaceutical company focused on developing innovative therapies in neuropsychiatry.

ATAI Life Sciences AG is a clinical-stage biopharmaceutical company headquartered in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative treatments for mental health disorders, addressing significant unmet medical needs. ATAI employs a decentralized, technology-driven platform model to accelerate the development of therapies. Its diverse portfolio includes product candidates such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and GRX-917 (Deuterated etifoxine), among others. By pooling expertise and resources, ATAI aims to create impactful, evidence-based therapies that can transform mental health treatment. The company operates primarily in Germany and the United States.

Psy Therapeutics is focused on discovering and developing innovative medicines aimed at improving the lives of individuals affected by central nervous system (CNS) disorders. The company engages in research to identify effective drug targets for CNS diseases and employs screening platforms and various research and development tools. Its efforts are concentrated on creating treatments for conditions such as anxiety disorders, major depressive disorder, and dementia, thereby providing healthcare professionals with advanced therapeutic options.

COMPASS Pathways is a mental health care company focused on developing innovative treatments for mental health conditions. It specializes in the formulation of COMP360, a psilocybin-based therapy currently undergoing Phase IIb clinical trials aimed at treating patients with treatment-resistant depression. The company operates across multiple sites in Europe and North America, conducting large-scale clinical trials to evaluate the efficacy and safety of its psilocybin therapy. Founded in 2016 and incorporated in 2020, COMPASS Pathways is headquartered in Altrincham, Cheshire, United Kingdom. The company's mission is to enhance patient access to evidence-based mental health solutions.